{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:34:38Z","timestamp":1787578478820,"version":"build-2736575974"},"reference-count":32,"publisher":"Elsevier BV","issue":"8","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","lipidjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Lipidology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.jacl.2026.05.238","type":"journal-article","created":{"date-parts":[[2026,6,9]],"date-time":"2026-06-09T16:41:57Z","timestamp":1781023317000},"page":"1616-1623","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Maternal and fetal outcomes of lipid-lowering drug use in pregnancy: A Czech nationwide study"],"prefix":"10.1016","volume":"20","author":[{"given":"Pavla","family":"Jadrn\u00ed\u010dkov\u00e1","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan","family":"V\u00e1clav\u00edk","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji\u0159\u00ed","family":"Jarkovsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Lahodn\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Filip","family":"Dubsk\u00fd","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jacl.2026.05.238_bib1","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1097\/MOL.0000000000000927","article-title":"Lipid metabolism during pregnancy: consequences for mother and child","volume":"35","author":"Mulder","year":"2024","journal-title":"Curr Opin Lipidol"},{"issue":"43","key":"10.1016\/j.jacl.2026.05.238_bib2","doi-asserted-by":"crossref","first-page":"4462","DOI":"10.1093\/eurheartj\/ehaf193","article-title":"2025 ESC guidelines for the management of cardiovascular disease and pregnancy","volume":"46","author":"De Backer","year":"2025","journal-title":"Eur Heart J"},{"key":"10.1016\/j.jacl.2026.05.238_bib3","unstructured":"FDA Requests removal of strongest warning against using cholesterol-lowering statins during pregnancy. Accessed August 14, 2024. https:\/\/www.fda.gov\/drugs\/fda-drug-safety-podcasts\/fda-requests-removalstrongest-warning-against-using-cholesterol-lowering-statins-during-pregnancy."},{"issue":"4","key":"10.1016\/j.jacl.2026.05.238_bib4","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1111\/1471-0528.12066","article-title":"Pregnancy outcome following maternal exposure to statins: a multicentre prospective study","volume":"120","author":"Winterfeld","year":"2013","journal-title":"BJOG"},{"issue":"7","key":"10.1016\/j.jacl.2026.05.238_bib5","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1002\/pds.4176","article-title":"Statins during pregnancy: a cohort study using the General Practice Research Database to investigate pregnancy loss","volume":"26","author":"McGrogan","year":"2017","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.jacl.2026.05.238_bib6","doi-asserted-by":"crossref","first-page":"h1035","DOI":"10.1136\/bmj.h1035","article-title":"Statins and congenital malformations: cohort study","volume":"350","author":"Bateman","year":"2015","journal-title":"BMJ"},{"issue":"5","key":"10.1016\/j.jacl.2026.05.238_bib7","doi-asserted-by":"crossref","first-page":"1081","DOI":"10.1016\/j.jacl.2016.07.002","article-title":"The risks of statin use in pregnancy: a systematic review","volume":"10","author":"Karalis","year":"2016","journal-title":"J Clin Lipidol"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib8","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1503\/cmaj.070150","article-title":"Maternal age and risk of stillbirth: a systematic review","volume":"178","author":"Huang","year":"2008","journal-title":"Can Med Assoc J"},{"issue":"9","key":"10.1016\/j.jacl.2026.05.238_bib9","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1111\/bcp.15423","article-title":"Pregnancy outcomes following maternal exposure to statins: a systematic review and meta-analysis","volume":"88","author":"Karadas","year":"2022","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.jacl.2026.05.238_bib10","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1093\/eurheartj\/ehaf592","article-title":"Statin use in pregnancy and risk of congenital malformations: a Norwegian nationwide study","volume":"47","author":"Christensen","year":"2025","journal-title":"Eur Heart J"},{"issue":"suppl_1","key":"10.1016\/j.jacl.2026.05.238_bib11","article-title":"Antihypertensive treatment during pregnancy and maternal and fetal outcomes","volume":"45","author":"Vaclavik","year":"2024","journal-title":"Eur Heart J"},{"issue":"10","key":"10.1016\/j.jacl.2026.05.238_bib12","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1111\/aogs.14225","article-title":"High maternal blood lipid levels during early pregnancy are associated with increased risk of congenital heart disease in offspring","volume":"100","author":"Cao","year":"2021","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"25","key":"10.1016\/j.jacl.2026.05.238_bib13","doi-asserted-by":"crossref","first-page":"7685","DOI":"10.1080\/14767058.2021.1960968","article-title":"\u201cMaternal diabetes mellitus and its impact on the risk of delivering a child with congenital heart disease: a systematic review and meta-analysis.\u201d","volume":"35","author":"Papazoglou","year":"2022","journal-title":"J Matern Fetal Neonatal Med"},{"issue":"3","key":"10.1016\/j.jacl.2026.05.238_bib14","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1001\/jama.1984.03340270043026","article-title":"The lipid research clinics coronary primary prevention trial results. II. the relationship of reduction in incidence of coronary heart disease to cholesterol lowering","volume":"251","year":"1984","journal-title":"JAMA"},{"key":"10.1016\/j.jacl.2026.05.238_bib15","unstructured":"FDACholestyramine powder for suspension.\u00a0Accessed May 2, 2026. \u3008https:\/\/fda.report\/DailyMed\/ac385fd9-fb8c-461f-959c-322c38f4515e\u3009."},{"issue":"3","key":"10.1016\/j.jacl.2026.05.238_bib16","doi-asserted-by":"crossref","first-page":"894","DOI":"10.1053\/j.gastro.2005.06.019","article-title":"Efficacy and safety of ursodeoxycholic acid versus cholestyramine in intrahepatic cholestasis of pregnancy","volume":"129","author":"Kondrackiene","year":"2005","journal-title":"Gastroenterology"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib17","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1471-0528.1995.tb09077.x","article-title":"Severe fetal intracranial haemorrhage during treatment with cholestyramine for intrahepatic cholestasis of pregnancy","volume":"102","author":"Sadler","year":"1995","journal-title":"Br J Obstet Gynaecol"},{"issue":"1","key":"10.1016\/j.jacl.2026.05.238_bib18","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.atherosclerosis.2009.03.008","article-title":"Peroxisome proliferator-activated receptor-alpha (PPAR\u03b1): at the crossroads of obesity, diabetes and cardiovascular disease","volume":"205","author":"Fruchart","year":"2009","journal-title":"Atherosclerosis"},{"issue":"10","key":"10.1016\/j.jacl.2026.05.238_bib19","doi-asserted-by":"crossref","first-page":"1649","DOI":"10.1016\/j.jacc.2005.02.052","article-title":"Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia","volume":"45","author":"Koh","year":"2005","journal-title":"J Am Coll Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib20","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1016\/j.jhep.2023.04.014","article-title":"Use of fenofibrate for intrahepatic cholestasis of pregnancy","volume":"79","author":"Grady","year":"2023","journal-title":"J Hepatol"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib21","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1097\/AOG.0b013e31820755b5","article-title":"Hyperlipidemia-associated pancreatitis in pregnancy managed with fenofibrate","volume":"117","author":"Whitten","year":"2011","journal-title":"Obstet Gynecol"},{"issue":"15","key":"10.1016\/j.jacl.2026.05.238_bib22","doi-asserted-by":"crossref","first-page":"1943","DOI":"10.1161\/01.CIR.0000034044.95911.DC","article-title":"Inhibition of intestinal cholesterol absorption by ezetimibe in humans","volume":"106","author":"Sudhop","year":"2002","journal-title":"Circulation"},{"issue":"25","key":"10.1016\/j.jacl.2026.05.238_bib23","doi-asserted-by":"crossref","first-page":"2387","DOI":"10.1056\/NEJMoa1410489","article-title":"Ezetimibe added to statin therapy after acute coronary syndromes","volume":"372","author":"Cannon","year":"2015","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib24","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/j.atherosclerosis.2012.02.016","article-title":"Lipid-altering efficacy of ezetimibe plus statin and statin monotherapy and identification of factors associated with treatment response: a pooled analysis of over 21,000 subjects from 27 clinical trials","volume":"223","author":"Morrone","year":"2012","journal-title":"Atherosclerosis"},{"key":"10.1016\/j.jacl.2026.05.238_bib25","doi-asserted-by":"crossref","first-page":"502","DOI":"10.1016\/j.atherosclerosis.2018.05.038","article-title":"Statins and other lipid-lowering therapy and pregnancy outcomes in homozygous familial hypercholesterolaemia: a retrospective review of 39 pregnancies","volume":"277","author":"Botha","year":"2018","journal-title":"Atherosclerosis"},{"issue":"48","key":"10.1016\/j.jacl.2026.05.238_bib26","doi-asserted-by":"crossref","first-page":"5047","DOI":"10.1093\/eurheartj\/ehac615","article-title":"Effect of inclisiran on lipids in primary prevention: the ORION-11 trial","volume":"43","author":"Ray","year":"2022","journal-title":"Eur Heart J"},{"issue":"16","key":"10.1016\/j.jacl.2026.05.238_bib27","doi-asserted-by":"crossref","first-page":"1507","DOI":"10.1056\/NEJMoa1912387","article-title":"Two phase 3 trials of inclisiran in patients with elevated LDL cholesterol","volume":"382","author":"Ray","year":"2020","journal-title":"N Engl J Med"},{"issue":"8","key":"10.1016\/j.jacl.2026.05.238_bib28","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1093\/eurjpc\/zwad402","article-title":"Genetically proxied low-density lipoprotein cholesterol lowering via PCSK9-inhibitor drug targets and risk of congenital malformations","volume":"31","author":"Ardissino","year":"2024","journal-title":"Eur J Prev Cardiol"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib29","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1002\/cpt.3269","article-title":"Safety of monoclonal antibodies inhibiting PCSK9 in pregnancy: disproportionality analysis in VigiBase\u00ae","volume":"116","author":"Noseda","year":"2024","journal-title":"Clin Pharmacol Ther"},{"issue":"21","key":"10.1016\/j.jacl.2026.05.238_bib30","doi-asserted-by":"crossref","first-page":"2119","DOI":"10.1056\/NEJMoa2511778","article-title":"Phase 1 trial of CRISPR-Cas9 gene editing targeting ANGPTL3","volume":"393","author":"Laffin","year":"2025","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.jacl.2026.05.238_bib31","doi-asserted-by":"crossref","first-page":"e56583","DOI":"10.1371\/journal.pone.0056583","article-title":"Advanced maternal age and adverse pregnancy outcome: evidence from a large contemporary cohort","volume":"8","author":"Kenny","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.jacl.2026.05.238_bib32","doi-asserted-by":"crossref","first-page":"g2301","DOI":"10.1136\/bmj.g2301","article-title":"Chronic hypertension and pregnancy outcomes: systematic review and meta-analysis","volume":"348","author":"Bramham","year":"2014","journal-title":"BMJ"}],"container-title":["Journal of Clinical Lipidology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426003843?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1933287426003843?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:10:46Z","timestamp":1787577046000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1933287426003843"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":32,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S1933287426003843"],"URL":"https:\/\/doi.org\/10.1016\/j.jacl.2026.05.238","relation":{},"ISSN":["1933-2874"],"issn-type":[{"value":"1933-2874","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Maternal and fetal outcomes of lipid-lowering drug use in pregnancy: A Czech nationwide study","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Lipidology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jacl.2026.05.238","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 National Lipid Association. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}